Cocrystal Product Pipeline

Targeting Viral Diseases with Pan-Genotypic Inhibitors

Our proprietary structural information, enzymology and nucleoside inhibitor expertise enable us to develop novel antiviral agents.

Viral Replication Enzymes are Clinically Proven Targets for Small Molecule Drugs

Replication enzymes are considered the Achilles heel of viruses and are essential for viral proliferation.

HCV Development: Three Different Classes of Drugs

Viral Disease Lead Discovery Lead Optimization Preclinical Regulatory Filing Phase 1
Hepatitis C CC-31244 (NNI)
Lead Discovery Phase complete
Lead Optimization Phase complete
Preclinical Phase complete
Regulatory Filing Phase complete
Phase 1 Phase in progress
Hepatitis C CC-2850 (Nuc)
Lead Discovery Phase complete
Lead Optimization Phase complete
Preclinical Phase in progress
Regulatory Filing Phase not started
Phase 1 Phase not started
Hepatitis C CC-2069 (NS5A)
Lead Discovery Phase complete
Lead Optimization Phase complete
Preclinical Phase in progress
Regulatory Filing Phase not started
Phase 1 Phase not started
Influenza Inhibitor
Lead Discovery Phase complete
Lead Optimization Phase in progress
Preclinical Phase not started
Regulatory Filing Phase not started
Phase 1 Phase not started
Norovirus (Nuc/non-Nuc)
Lead Discovery Phase complete
Lead Optimization Phase in progress
Preclinical Phase not started
Regulatory Filing Phase not started
Phase 1 Phase not started

CC-31244: A Pan-Genotypic Non-Nucleoside Inhibitor

The first-in-human study (Phase 1a/1b) to evaluate safety, antiviral activity and pharmacokinetics of CC-31244 was initiated in April, 2016 and currently ongoing.

View CC-31244

CC-2850: A Pan-Genotypic Nucleoside Prodrug

CC-2850 is currently undergoing pre-clinical studies.

View CC-2850

CC-2069: A Pan-Genotypic NS5A Inhibitor

CC-2069 is currently undergoing pre-clinical studies.

View CC-2069